BridgeBio Pharma (NASDAQ:BBIO) Sets New 12-Month High – Here’s Why

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) reached a new 52-week high during trading on Thursday . The stock traded as high as $84.06 and last traded at $79.8380, with a volume of 788746 shares changing hands. The stock had previously closed at $73.33.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 met its primary endpoint (AHV) with a mean treatment difference vs. placebo of +2.10 cm/year; key secondary measures (height Z-score, body proportionality in <8-year-olds) also improved and safety was clean — company plans NDA/MAA submissions H2 2026. BridgeBio Reports Positive Phase 3 Topline Results
• Positive Sentiment: Market reaction: multiple outlets report BBIO stock jumped on the infigratinib readout while rivals (e.g., BioMarin, Ascendis) fell — the data appear to change the competitive landscape for achondroplasia treatments. BridgeBio stock jumps after positive Phase 3 results
• Neutral Sentiment: Short-interest reports in feeds show anomalous/zero values for February (likely data/reporting artifact) and do not provide a clear signal about bearish positioning right now.
• Negative Sentiment: Zacks warns BridgeBio may report negative earnings in the upcoming quarter and lacks setup for an earnings beat; near-term EPS weakness or guidance shortfalls could weigh on the stock despite the clinical win. BridgeBio Pharma (BBIO) May Report Negative Earnings
• Negative Sentiment: Quiver/other data note heavy insider selling activity in recent periods — a potential governance/stock-sentiment negative that investors may watch, even though the clinical news is currently dominant. QuiverQuant PROPEL 3 summary & insider notes

Analysts Set New Price Targets

A number of research firms have commented on BBIO. JPMorgan Chase & Co. lifted their price objective on shares of BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. TD Cowen reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Evercore reaffirmed an “outperform” rating on shares of BridgeBio Pharma in a research report on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. Finally, Truist Financial increased their price target on BridgeBio Pharma from $80.00 to $86.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Twenty-two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $79.05.

BridgeBio Pharma Stock Up 5.5%

The company has a market cap of $14.91 billion, a price-to-earnings ratio of -18.52 and a beta of 1.13. The business has a fifty day simple moving average of $75.54 and a 200 day simple moving average of $62.79.

Insider Activity

In other BridgeBio Pharma news, Director Randal W. Scott sold 10,000 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $66.65, for a total transaction of $666,500.00. Following the transaction, the director directly owned 11,589 shares in the company, valued at approximately $772,406.85. This represents a 46.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $73.97, for a total value of $2,958,800.00. Following the completion of the transaction, the chief executive officer directly owned 735,686 shares of the company’s stock, valued at $54,418,693.42. The trade was a 5.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 260,700 shares of company stock valued at $18,157,071 in the last quarter. Insiders own 18.20% of the company’s stock.

Institutional Investors Weigh In On BridgeBio Pharma

Institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio increased its holdings in BridgeBio Pharma by 1.1% during the 3rd quarter. Strs Ohio now owns 18,600 shares of the company’s stock valued at $966,000 after acquiring an additional 200 shares in the last quarter. GAMMA Investing LLC grew its position in shares of BridgeBio Pharma by 28.6% in the third quarter. GAMMA Investing LLC now owns 1,020 shares of the company’s stock valued at $53,000 after purchasing an additional 227 shares during the last quarter. Steward Partners Investment Advisory LLC grew its position in shares of BridgeBio Pharma by 22.3% in the second quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company’s stock valued at $54,000 after purchasing an additional 228 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of BridgeBio Pharma by 91.4% during the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after purchasing an additional 245 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D raised its position in shares of BridgeBio Pharma by 0.5% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 51,896 shares of the company’s stock worth $3,970,000 after purchasing an additional 246 shares during the last quarter. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.